CZ.02.1.01/0.0/0.0/16_019/0000787 Fighting Infectious Diseases, awarded by the Ministry of Education, Youth and Sports of the Czech Republic, financed from The European Regional Development Fund, GAUK No
Lactoferrin in health and disease
Indications include: Medically refractory disease not responding to optimized biologic therapy Bowel obstruction from fibrostenotic stricture Intra-abdominal abscess not amenable to percutaneous drainage Complex perianal fistula (seton placement, diversion) Enterocutaneous or enterovesical fistula Dysplasia or cancer in Crohns colitis Free perforation (rare) Nutritional Therapy Exclusive enteral nutrition (EEN) effective for induction in pediatric Crohns
Composition BPC-157: 10 mg Appearance: Lyophilized powder in a sealed research vial Research Focus (non-clinical) Peptide identity and purity assessment via HPLC/LC-MS Assay development and calibration for quantitative analysis Chromatographic method optimization for impurity profiling Stability characterization of a lyophilized peptide under laboratory storage conditions Documentation Lot-specific COA available (HPLC/LC-MS) Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA (HPLC/LC-MS) with verification key Third-party verification link provided per lot (Janoshik) Lyophilized for transit stability
Clinicians working in hormone replacement therapy and metabolic medicine are well-positioned to evaluate these interactions and structure peptide protocols accordingly
Side effects for both injectable drugs are generally mild
